31181-64-3

Usage

Chemical Properties

Type of white crystal

InChI:InChI=1/C6H6BrNO/c1-5-2-3-6(7)4-8(5)9/h2-4H,1H3

Upstream product

• 3430-13-5 5-bromo-2-methylpyridine 
• 109-06-8 α-picoline 

Downstream Products

• 88139-91-7 (5-bromopyridin-2-yl)methanol 
• 62516-08-9 5-bromo-2-methyl-4-nitropyridine 1-oxide 
• 900186-89-2 C₂HF₃O₂*C₆H₆BrNO 
• 431-47-0 trifluoroacetic acid-methyl ester 
• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 192642-82-3 6-bromo-[1,2,3]triazolo[1,5-a]pyridine 
• 192642-97-0 (E,Z)-N’-((5-bromopyridin-2-yl)methylene)-4-methylbenzene-sulfonohydrazide 
• 103971-44-4 4-chloro-5-bromo-2-hydroxymethylpyridine 
• 717843-48-6 3-bromo-6-methylpyridine-2-carbonitrile 
• 1260162-47-7 N-(5-(2,5-dichlorophenyl)-2-methylpyridin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 380893-73-2 [(5-bromo-2-pyridinyl)methyl]-phosphonic acid diethyl ester 
• 168823-76-5 5-bromo-2-(chloromethyl)pyridine 
• 1060802-25-6 5-bromo-4-chloropicolinic acid 
• 1260162-97-7 N-[5-(3-chlorophenyl)-2-methylpyridin-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide 

Relevant academic research and scientific papers

A Reactive, Rigid GdIII Labeling Tag for In-Cell EPR Distance Measurements in Proteins

The cellular environment of proteins differs considerably from in vitro conditions under which most studies of protein structures are carried out. Therefore, there is a growing interest in determining dynamics and structures of proteins in the cell. A key factor for in-cell distance measurements by the double electron–electron resonance (DEER) method in proteins is the nature of the used spin label. Here we present a newly designed GdIII spin label, a thiol-specific DOTA-derivative (DO3MA-3BrPy), which features chemical stability and kinetic inertness, high efficiency in protein labelling, a short rigid tether, as well as favorable spectroscopic properties, all are particularly suitable for in-cell distance measurements by the DEER method carried out at W-band frequencies. The high performance of DO3MA-3BrPy-GdIII is demonstrated on doubly labelled ubiquitin D39C/E64C, both in vitro and in HeLa cells. High-quality DEER data could be obtained in HeLa cells up to 12 h after protein delivery at in-cell protein concentrations as low as 5–10 μm.

IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF

The present disclosure provides compounds represented by Formula (I) wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula (I) are FED inhibitors. FED inhibitors are useful for the treatment of cancer and other diseases.

FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF

The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I′), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I′) is the same as defined in the specification.

Full synthesis of natural-product (+/-)-cananga odorata alkali and separation method of enantiomers

The invention discloses full synthesis of natural-product (+/-)-cananga odorata alkali and a chiral separation method of enantiomers thereof and belongs to the technical field of organic synthesis. The chiral separation method comprises the following steps of: adopting natural-product (+/-)-anthorine G as a substrate, carrying out tetrahydrofuran/methyl lithium reaction to obtain the natural-product (+/-)-cananga odorata alkali and the enantiomers thereof; then using a chiral semi-preparative type high-performance liquid chromatograph to carry out separation on the enantiomers, and obtaining the cananga odorata alkali and the enantiomers with the total yield being 17.9%. The full synthesis and the chiral separation method disclosed by the invention have the beneficial effects that the synthesis method is simplified, the total yield of full synthesis is increased, the structure identification is carried out, and not only is the divergence on the specific rotation of the cananga odorataalkali solved, but also basis and powerful guarantee are provided for further study on the compounds.

DO3A type highly stable paramagnetic probe capable of being used for intracellular magnetic resonance research and preparation method of DO3A type highly stable paramagnetic probe

The invention provides a DO3A type highly stable paramagnetic probe T1 capable of being used for intracellular magnetic resonance research and a preparation method of the DO3A type highly stable paramagnetic probe T1. The structural formula of the paramag

INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF

The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as i

Method for totally synthesizing natural product (+/-)-rupestine G and resolving enantiomers

The invention relates to a method for totally synthesizing a natural product (+/-)-rupestine G and resolving enantiomers. The method comprises the following steps: oxidizing the raw material 2-methyl-5-bromopyridine (1) by m-chloroperoxybenzoic acid to obtain a nitrogen oxidation product compound 2, carrying out a Reissert-Henze reaction to perform cyano substitution so as to obtain a compound 3, carrying out a decarboxylation reaction on the compound 3 and potassium monoethyl malonate to obtain beta-ketoester 4, carrying out alkylation under the condition of sodium ethylate to obtain a compound 5, carrying out a coupling reaction to obtain a compound 6, carrying out an intramolecular olefin double replacement reaction on the compound 6 to obtain a key intermediate compound 7, carrying out reduction with sodium borohydride to obtain a compound 8, carrying out a reaction under the condition of pyridine/MsCl to obtain a compound 9, hydrolyzing the compound 9 under the action of lithium hydroxide, carrying out methyl esterification by using iodomethane to obtain a compound 10, carrying out palladium-carbon catalytic hydrogenation to obtain a pair of diastereoisomers 11 and 12, and carrying out resolution by a semi-preparative high performance liquid chromatograph to obtain the natural product rupestine G and three stereoisomers, namely a compound 13, a compound 14 and a compound 15.

Preparation method of 3-bromo-6-methyl-2-pyridylaldehyde

The invention relates to a preparation method of 3-bromo-6-methyl-2-pyridylaldehyde. The 3-bromo-6-methyl-2-pyridylaldehyde is an important medical intermediate and has wide market prospects. The 3-bromo-6-methyl-2-pyridylaldehyde can be condensed with amino groups to form an N-containing Schiff alkali conjugated system; and both N atoms on the pyridine ring and N atoms on imino C=N outside the ring can be coordinated with metal ions to form functional complexes. The preparation method comprises the following step: by using 5-bromo-2-methylpyridine as an initial raw material, carrying out N-oxidation, cyanation, acidification, esterification, reduction and aldehyde reaction to obtain the product 3-bromo-6-methyl-2-pyridylaldehyde. The 3-bromo-6-methyl-2-pyridylaldehyde synthesized by the method has the advantages of high purity, high yield and lower production cost. The synthesis method is simple and easy to implement, is green and environment-friendly, and provides theoretical and experimental references for industrial production.

Homogenous suspension of immunopotentiating compounds and uses thereof

The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.

AROMATIC RING COMPOUND

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.